Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 3/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | CSK | P41240 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388384 | 0.81 | SMN1; SMN2 (0.61) | LPLLIPGCA2ALDH1A1FFAR1 | |
| SCHEMBL671341 | 0.79 | PKM (0.44) | PKMLPLLIPGALDH1A1FFAR1 | |
| SCHEMBL17285630 | 0.78 | FFAR1 (0.65) | PKMGAAALDH1A1FFAR1SMN1; SMN2 | |
| SCHEMBL6208171 | 0.78 | PKM (0.58) | PKMGAACA2ALDH1A1FFAR1 | |
| SCHEMBL787870 | 0.78 | PKM (0.62) | PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL13476511 | 0.78 | LMNA (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL941105 | 0.76 | SMN1; SMN2 (0.66) | PKMGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL3430422 | 0.76 | PKM (0.56) | PKMGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL3428545 | 0.76 | PKM (0.56) | PKMGAAALDH1A1FFAR1SMN1; SMN2 | |
| SCHEMBL1251803 | 0.76 | PKM (0.56) | PKMGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PKM 1584/4885GAA 2877/4885LPL 3791/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | PKM 1584/4885GAA 2877/4885LPL 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.